{"id":"moxifloxacin-ethambutol-isoniazid-pyrazinamide-rifampicin","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, vomiting, diarrhea)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Optic neuritis (ethambutol-related)"},{"rate":null,"effect":"Photosensitivity (moxifloxacin-related)"}]},"_chembl":{"chemblId":"CHEMBL614","moleculeType":"Small molecule","molecularWeight":"123.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Moxifloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase; Rifampicin inhibits bacterial RNA polymerase; Isoniazid and Pyrazinamide inhibit mycobacterial cell wall synthesis and metabolism; Ethambutol inhibits arabinosyl transferases involved in cell wall synthesis. The combination provides synergistic activity against drug-susceptible and multidrug-resistant tuberculosis.","oneSentence":"This is a fixed-dose combination of five anti-tuberculosis agents that work through multiple mechanisms to inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication in Mycobacterium tuberculosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:05.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (drug-susceptible and multidrug-resistant forms)"}]},"trialDetails":[{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT07227779","phase":"PHASE2","title":"B-PaLMZ for TB Meningitis","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-02-15","conditions":"Tuberculous Meningitis","enrollment":240},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05807399","phase":"PHASE2","title":"PanACEA - STEP2C -01","status":"RECRUITING","sponsor":"Michael Hoelscher","startDate":"2023-04-14","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":390},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT06917495","phase":"PHASE2","title":"Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2025-04-05","conditions":"Mild Spinal Tuberculosis","enrollment":300},{"nctId":"NCT02410772","phase":"PHASE3","title":"TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-01-25","conditions":"Tuberculosis","enrollment":2516},{"nctId":"NCT04856644","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2020-01-01","conditions":"Tuberculosis, Pulmonary","enrollment":333},{"nctId":"NCT03338621","phase":"PHASE2, PHASE3","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2018-07-30","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":455},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT05401071","phase":"PHASE2, PHASE3","title":"Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2023-01-13","conditions":"Tuberculosis, Pulmonary","enrollment":2442},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT05575518","phase":"PHASE3","title":"A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Stellah Mpagama","startDate":"2023-08-11","conditions":"Tuberculosis, Human Immunodeficiency Virus","enrollment":414},{"nctId":"NCT05454345","phase":"PHASE3","title":"Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-10-01","conditions":"Tuberculosis, Pulmonary","enrollment":620},{"nctId":"NCT01154959","phase":"PHASE3","title":"Latency in Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Tuberculosis Research Centre, India","startDate":"2010-02","conditions":"Pulmonary Tuberculosis","enrollment":120},{"nctId":"NCT04545788","phase":"NA","title":"Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2020-08-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT04187469","phase":"NA","title":"Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-03-01","conditions":"Pulmonary Tuberculosis","enrollment":286},{"nctId":"NCT02114684","phase":"PHASE1, PHASE2","title":"Improving Retreatment Success (IMPRESS)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2013-11","conditions":"Recurrent Tuberculosis","enrollment":197},{"nctId":"NCT02193776","phase":"PHASE2","title":"A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-10-23","conditions":"Tuberculosis","enrollment":240},{"nctId":"NCT02342886","phase":"PHASE3","title":"Shortening Treatment by Advancing Novel Drugs","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-02","conditions":"Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant","enrollment":284},{"nctId":"NCT03625739","phase":"","title":"Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2018-07-01","conditions":"Tuberculosis","enrollment":800},{"nctId":"NCT01589497","phase":"PHASE2","title":"Essentiality of INH in TB Therapy","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2015-06-30","conditions":"Tuberculosis","enrollment":69},{"nctId":"NCT01785186","phase":"PHASE2","title":"Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2013-04","conditions":"Tuberculosis, Pulmonary","enrollment":365},{"nctId":"NCT00728507","phase":"PHASE2","title":"Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2009-11","conditions":"Tuberculosis","enrollment":121},{"nctId":"NCT00864383","phase":"PHASE3","title":"Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2008-01","conditions":"Pulmonary Tuberculosis","enrollment":1931},{"nctId":"NCT01215851","phase":"PHASE2","title":"Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2010-10","conditions":"Pulmonary Tuberculosis","enrollment":85},{"nctId":"NCT02331823","phase":"PHASE4","title":"Research on New Regimens for Retreatment Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2013-06","conditions":"Reinfection Pulmonary Tuberculosis","enrollment":864},{"nctId":"NCT00144417","phase":"PHASE2","title":"TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2006-02","conditions":"Tuberculosis","enrollment":433},{"nctId":"NCT00140309","phase":"PHASE2","title":"TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2003-07","conditions":"Tuberculosis, Pulmonary","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":86,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avelox","Avelon","Avalox","Myambutol","Nydrazid"],"phase":"phase_3","status":"active","brandName":"Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin","genericName":"Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin","companyName":"Global Alliance for TB Drug Development","companyId":"global-alliance-for-tb-drug-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of five anti-tuberculosis agents that work through multiple mechanisms to inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication in Mycobacterium tuberculosis. Used for Tuberculosis (drug-susceptible and multidrug-resistant forms).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}